FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912491673> ?p ?o ?g. }

• W2912491673 endingPage "4143" @default.
• W2912491673 startingPage "4143" @default.
• W2912491673 abstract "Abstract Background: Hairy Cell Leukemia (HCL) is a rare hematological malignancy, comprising only of 2% of all leukemias, with an estimated 900 new cases diagnosed each year in the United States. HCL displays a characteristic immunophenotypic profile that include pan-B cell markers including CD103, CD11c, and CD25. World Health Organization guidelines defines two forms of HCL, classic HCL (cHCL) and variant HCL (HCLv) as two distinct clinical entities. Patients with cHCL have a distinct immunophenotypic profile on their malignant leukemic cells including CD20+, CD19+, CD11c+, CD25+, CD103+, and CD123+, while the leukemic cells from patients with HCLv show CD11c+, CD20+ and CD19+, while lacking CD25 and CD123 expression. Some patients with cHCL will retain CD25 positivity while demonstrating negativity for other typical markers, herein termed atypical HCL (aHCL). Presence or absence of CD25 is an important determinant in classifying patients into cHCL and HCLv. Although it has previously been reported that CD25 expression may be lost during treatment with the targeted agent vemurafenib, we sought to identify whether this immunophenotypic change occurs following other treatment types, including standard purine nucleoside analog therapy and with targeted BTK inhibition. Methods: Adult patients (≥18 years) with a diagnosis of HCL whom had immunophenotype data collected before and after treatment between 2010 and 2018 were included in the study. Immunophenotype and morphological characteristics of initial and follow-up peripheral blood, bone marrow aspirate, and core biopsy specimens were reviewed and correlated with the treatment received. Results: We evaluated 30 HCL patients who underwent different therapies. All available specimens were reviewed and showed morphologic features characteristic for cHCL (n=26, 86.7%), and aHCL (n=4, 13.3%). The median age at HCL diagnosis was 50 years (44-76 years) with male predominance (76%). Patients with aHCL were treated with ibrutinib (n=2) and pentostatin (n=2). Patients with cHCL were treated with pentostatin (n=12), ibrutinib (n=8), vemurafenib (n=4), dabrafenib (n=1), and cladribine (n=1). Bone marrow analyses showed that all the patients had leukemic B-lymphocyte co-expression of CD19, CD20, CD103, CD11c, CD25, and CD123 prior to treatment. Some patients also had a smaller percentage of lymphocytes lacking CD25 expression along with the CD25 positive lymphocytes. Follow-up bone marrow and peripheral blood analysis showed that almost half (n=14, 46%) of treated patients had a partial or complete loss of CD25 expression regardless of the treatment type. Leukemic cells continued to express other HCL signature markers. Conclusion: Our study indicates that during the course of disease some patients display a loss of CD25 expression after therapy. This phenomenon was observed across different therapies and is not specific to the type of treatment. This is the first study to show treatment-dependent CD25 variability with pentostatin, ibrutinib and dabrafenib. Our results advocate for caution when using CD25 for the differential diagnosis of cHCL versus HCLv in treated patients. Future studies are needed in larger patient cohorts to determine the overall role and utility of CD25 in the diagnosis of cHCL and HCLv. Disclosures Lozanski: Genentech: Research Funding; Stem Line: Research Funding; BI: Research Funding; Novartis: Research Funding; Beckman: Research Funding; Coulter: Research Funding. Andritsos:Astra Zeneca: Consultancy; HCLF: Membership on an entity's Board of Directors or advisory committees." @default.
• W2912491673 created "2019-02-21" @default.
• W2912491673 creator A5018821266 @default.
• W2912491673 creator A5039283256 @default.
• W2912491673 creator A5042260558 @default.
• W2912491673 creator A5044008222 @default.
• W2912491673 creator A5045921288 @default.
• W2912491673 creator A5051619378 @default.
• W2912491673 creator A5055443268 @default.
• W2912491673 creator A5069844171 @default.
• W2912491673 creator A5078508615 @default.
• W2912491673 creator A5080781659 @default.
• W2912491673 creator A5085565650 @default.
• W2912491673 date "2018-11-29" @default.
• W2912491673 modified "2023-10-16" @default.
• W2912491673 title "Down-Regulation of CD25 Antigen in Hairy Cell Leukemia Patients after Treatment" @default.
• W2912491673 doi "https://doi.org/10.1182/blood-2018-99-120043" @default.
• W2912491673 hasPublicationYear "2018" @default.
• W2912491673 type Work @default.
• W2912491673 sameAs 2912491673 @default.
• W2912491673 citedByCount "1" @default.
• W2912491673 countsByYear W29124916732023 @default.
• W2912491673 crossrefType "journal-article" @default.
• W2912491673 hasAuthorship W2912491673A5018821266 @default.
• W2912491673 hasAuthorship W2912491673A5039283256 @default.
• W2912491673 hasAuthorship W2912491673A5042260558 @default.
• W2912491673 hasAuthorship W2912491673A5044008222 @default.
• W2912491673 hasAuthorship W2912491673A5045921288 @default.
• W2912491673 hasAuthorship W2912491673A5051619378 @default.
• W2912491673 hasAuthorship W2912491673A5055443268 @default.
• W2912491673 hasAuthorship W2912491673A5069844171 @default.
• W2912491673 hasAuthorship W2912491673A5078508615 @default.
• W2912491673 hasAuthorship W2912491673A5080781659 @default.
• W2912491673 hasAuthorship W2912491673A5085565650 @default.
• W2912491673 hasConcept C126322002 @default.
• W2912491673 hasConcept C142724271 @default.
• W2912491673 hasConcept C147483822 @default.
• W2912491673 hasConcept C18031839 @default.
• W2912491673 hasConcept C196166836 @default.
• W2912491673 hasConcept C203014093 @default.
• W2912491673 hasConcept C2776090121 @default.
• W2912491673 hasConcept C2778461978 @default.
• W2912491673 hasConcept C2779338263 @default.
• W2912491673 hasConcept C2780483514 @default.
• W2912491673 hasConcept C502942594 @default.
• W2912491673 hasConcept C71924100 @default.
• W2912491673 hasConcept C79484868 @default.
• W2912491673 hasConcept C83396363 @default.
• W2912491673 hasConcept C8891405 @default.
• W2912491673 hasConceptScore W2912491673C126322002 @default.
• W2912491673 hasConceptScore W2912491673C142724271 @default.
• W2912491673 hasConceptScore W2912491673C147483822 @default.
• W2912491673 hasConceptScore W2912491673C18031839 @default.
• W2912491673 hasConceptScore W2912491673C196166836 @default.
• W2912491673 hasConceptScore W2912491673C203014093 @default.
• W2912491673 hasConceptScore W2912491673C2776090121 @default.
• W2912491673 hasConceptScore W2912491673C2778461978 @default.
• W2912491673 hasConceptScore W2912491673C2779338263 @default.
• W2912491673 hasConceptScore W2912491673C2780483514 @default.
• W2912491673 hasConceptScore W2912491673C502942594 @default.
• W2912491673 hasConceptScore W2912491673C71924100 @default.
• W2912491673 hasConceptScore W2912491673C79484868 @default.
• W2912491673 hasConceptScore W2912491673C83396363 @default.
• W2912491673 hasConceptScore W2912491673C8891405 @default.
• W2912491673 hasIssue "Supplement 1" @default.
• W2912491673 hasLocation W29124916731 @default.
• W2912491673 hasOpenAccess W2912491673 @default.
• W2912491673 hasPrimaryLocation W29124916731 @default.
• W2912491673 hasRelatedWork W1789272384 @default.
• W2912491673 hasRelatedWork W1990537997 @default.
• W2912491673 hasRelatedWork W2083525945 @default.
• W2912491673 hasRelatedWork W2359228087 @default.
• W2912491673 hasRelatedWork W2383893017 @default.
• W2912491673 hasRelatedWork W2912491673 @default.
• W2912491673 hasRelatedWork W2920414616 @default.
• W2912491673 hasRelatedWork W3028842595 @default.
• W2912491673 hasRelatedWork W3029440384 @default.
• W2912491673 hasRelatedWork W4206907810 @default.
• W2912491673 hasVolume "132" @default.
• W2912491673 isParatext "false" @default.
• W2912491673 isRetracted "false" @default.
• W2912491673 magId "2912491673" @default.
• W2912491673 workType "article" @default.